FIA
LPCN icon

FNY Investment Advisers’s Lipocine LPCN Stock Holding History

FNY Investment Advisers’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,567
Closed -$40.1K – 938
2019
Q3 		$74K Buy
1,567
+729
+87% +$29.3K 0.02% 352
2019
Q2 		$27K Buy
+838
New +$25.9K 0.01% 444

Other funds holding LPCN

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Mercer Global Advisors
Mercer Global Advisors Denver, Colorado $67.6B AUM 18.3% 1-Year Est. Return
CL
Choreo LLC Rockford, Illinois $8.15B AUM 20.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

FNY Investment Advisers's LPCN Position: Q4 2019 in Review

FNY Investment Advisers sold out of Lipocine (LPCN) in Q4 2019, closing a stake of 1,567 shares — an estimated $40.1K sold.

FNY Investment Advisers first reported a position in LPCN in Q2 2019 and held it in 2 quarters. The position peaked at $74K in Q3 2019. 32 funds tracked by Wall St. Rank hold LPCN as of Q4 2019.

  • FNY Investment Advisers reported no remaining Lipocine position as of Q4 2019 after selling out during the quarter.
  • FNY Investment Advisers sold 1,567 Lipocine shares in Q4 2019, an estimated $40.1K.
  • FNY Investment Advisers first reported a position in Lipocine in Q2 2019 and held it in 2 quarters.
  • FNY Investment Advisers's Lipocine position peaked at $74K in Q3 2019.
  • 32 funds tracked by Wall St. Rank held Lipocine as of Q4 2019.

Based on FNY Investment Advisers's 13F filing for Q4 2019, filed 10 Jan 2020.